AFM 11

Drug Profile

AFM 11

Alternative Names: AFM 11

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator Affimed Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Treatment-resistant, Recurrent) in Czech Republic (IV) (NCT02848911)
  • 06 Dec 2015 Pharmacodynamics data from a preclinical study in Cancer presented at the 57th Annual American Society of Haematology (ASH-Hem,
  • 10 Nov 2015 Affimed Therapeutics plans a phase I trial for Acute lymphocytic leukaemia in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top